NovoNorm
(repaglinide)ApprovedSmall molecule
Repaglinide is used to help people with type 2 diabetes control their blood sugar levels by stimulating the pancreas to release insulin, especially when taken before meals.[2] NovoNorm is currently approved and in use across 9 indications[4].[1]
NovoNorm is one of 262 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
9
Indications
62
Total Trials
4
Active Trials
261
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1NovoNorm
GGemini Therapeutics, Inc.
Approved
Zoladex
TTerSera Therapeutics LLC
Phase 3
Truqap
AstraZenecaPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Docetaxel /m²
AstraZenecaPhase 3
INR101
YYunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes15 trials
Show 12 more trials
Interaction11 trials
Show 8 more trials
Metformin3 trials
Tics3 trials
22 more indications
Type 2 Diabetes Mellitus2 trials
Observational Study2 trials
ART2 trials
Midazolam2 trials
Atorvastatin2 trials
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
Endothelial Function1 trial
Diabetes1 trial
Diabetes Therapy to Improve BMI and Lung Function in CF
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00072904·108 enrolled
Obese Patients1 trial
Caffeine1 trial
Lymphoma1 trial
Type 2 Diabetic Patients1 trial
Safety and Efficacy1 trial
Advanced Solid Tumor1 trial
Cystic Fibrosis1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Advanced Malignancies1 trial
TP53 Y220C Mutation1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 22, 1997
PRANDIN
NDA NDA020741
Sources
References
- [1]
- [2]MedlinePlus Drug Information — NovoNorm drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for repaglinide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sulfonylurea Receptor 1, Kir6.2 Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGemini Therapeutics, Inc.